ASH 2018: Phoenix and other DLBCL study updates
Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future… read more.
Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future… read more.
Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.
Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.
Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.
As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.
Among the late-breaking clinical trial abstracts at UEG Week were new data for ustekinumab in UC, a new formulation for subcutaneous administration of vedolizumab, and early clinical data… read more.
Professor Stefan Schreiber (Germany) discusses the future of therapies in IBD.
Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.
Dr Johan Burisch (Denmark) reviews data he presented on the cost saving effect of biological therapy in patients with IBD.
Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.
Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.